← Human Trials & Peer-Reviewed Studies

Effect of Hesperidin With and Without a Calcium (Calcilock) Supplement on Bone Health in Postmenopausal Women.

Plain-language guide to PMID 26751193 (2016): double-blind randomized controlled trial of Hesperidin in 12 women.

Key Facts

PMID
26751193
Journal
The Journal of clinical endocrinology and metabolism
Year
2016
Study type
Randomized Controlled Trial
Authors
Martin BR et al. (8 authors)
DOI
10.1210/jc.2015-3767
Registered trial
NCT01881204

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Hesperidin.

The objective of the study was to measure the effect of hesperidin with or without calcium supplementation on bone calcium retention in postmenopausal women.

Why It Was Studied

Citrus fruits contain unique flavanones.

Who Took Part

The abstract describes 12 women taking part.

PubMed indexes the participants as middle-aged adults and older adults, women only.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

The women were allocated by chance, so the Hesperidin group and the comparison group should start out alike.

As a double-blind Hesperidin study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Hesperidin could be set against what happens without it.

Each person switched between Hesperidin and the comparison at some point, usually with a gap in between.

Bone calcium retention was determined from urinary excretion of the rare isotope, (41)Ca, from bone.

What Was Measured

PubMed files the paper under topics including Bone and Bones, Calcium, Calcium Radioisotopes, Calcium, Dietary, Dietary Supplements, Hesperidin and Osteoporosis, Postmenopausal.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Hesperidin in 12 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 2 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: all human trials.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.